This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

Prescribing Information for SARCLISA® (isatuximab) can be found via the Product Card at the bottom of the page.

In this video, you'll learn about

The phase 3 ICARIA-MM study of an anti-CD38 monoclonal antibody triplet regimen in relapsed and refractory multiple myeloma(RRMM) presented by Dr Ramasamy.

SARCLISA® + Pd demonstrated a 40% risk reduction in progression or death vs Pd (11.53 vs 6.47 months [absolute change 5 months]; HR 0.596, 95% CI: 0.44, 0.81; p=0.001).1

Overview of SARCLISA®

Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.

Dosing and Administration Guide

Download a handy guide to SARCLISA dosing and administration information

Patient Booklet

Download SARCLISA® patient information.

Get in touch with the Oncology Team

Relapsed Refractory Multiple Myeloma Product


Prescribing Information GB


MAT-XU-2202578 (v2.0)
Date of preparation: August 2023

    1. Attal M, et al. Lancet. 2019;394:2096–107.

MAT-XU-2202565 (v1.0)
Date of Preparation: September 2023

This medicinal product is subject to additional monitoring.This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.